Search

Your search keyword '"Pfizer Inc. -- Research"' showing total 134 results
Start Over Descriptor "Pfizer Inc. -- Research"
134 results on '"Pfizer Inc. -- Research"'

101. Hospital gets subpoena tied to doctor's studies

Author

Armstrong, David and Winstein, Keith

Subjects
Wyeth -- Research, Wyeth -- Product information, Merck & Company Inc. -- Research, Merck & Company Inc. -- Product information, Pfizer Inc. -- Product information, Pfizer Inc. -- Research, Analgesics -- Research, Analgesics -- Reports, Anesthesiology -- Research, Hospitals -- United States, Hospitals -- Investigations, Hospitals -- Records and correspondence, Medical research -- Investigations, Medical research -- Records and correspondence, Medicine, Experimental -- Investigations, Medicine, Experimental -- Records and correspondence, Pharmaceutical industry -- Research, Pharmaceutical industry -- Product information, Physicians -- Investigations, Physicians -- Compensation and benefits, Research fraud -- Investigations, Research fraud -- Cases, Subpoena, Company legal issue, News, opinion and commentary, Celebrex (Medication) -- Reports, Celebrex (Medication) -- Research, Vioxx (Medication) -- Reports, Vioxx (Medication) -- Research
Published
2009

102. Pfizer tuts progress amid setbacks

Author

Johnson, Avery

Subjects
Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Drugs -- Product development, Drugs -- Research, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Pharmaceutical research -- Analysis, News, opinion and commentary
Published
2009

103. Pfizer plans layoffs in research; drug maker has little in pipeline to show for its $7.5 billion R&D budget

Author

Rockoff, Jonathan D.

Subjects
Pfizer Inc. -- Reorganization and restructuring, Pfizer Inc. -- Research, Pfizer Inc. -- Product development, Pfizer Inc. -- Securities, Pfizer Inc. -- Company sales and earnings, Layoffs -- Planning, Pharmaceutical industry -- Reorganization and restructuring, Pharmaceutical industry -- Research, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical research -- Analysis, Profit -- Analysis, Scientists -- Appointments, resignations and dismissals, Stocks -- Prices and rates, Technicians -- Appointments, resignations and dismissals, Company restructuring/company reorganization, Company organization, Company securities, Company earnings/profit, Company business planning, Company pricing policy, Layoff, News, opinion and commentary
Published
2009

104. Pfizer project looks at side effects; Boston hospitals to use electronic records to encourage doctor reporting

Author

Rockoff, Jonathan D.

Subjects
United States. Food and Drug Administration -- Reports, Pfizer Inc. -- Research, Drugs -- Analysis, Drugs -- Reports, Drugs -- Complications and side effects, Administrative agencies -- Reports, Hospitals -- United States, Hospitals -- Reports, Hospitals -- Research, Medical records -- Usage, Medical records -- Analysis, Pharmaceutical industry -- Research, Physicians -- Reports, Drugs -- Adverse and side effects, Drugs -- Measurement, News, opinion and commentary, Massachusetts General Hospital (Boston, Massachusetts) -- Research, Massachusetts General Hospital (Boston, Massachusetts) -- Reports, Brigham and Women's Hospital -- Research, Brigham and Women's Hospital -- Reports
Abstract

Massachusetts General Hospital and Brigham and Women's Hospital, both in Boston, Massachusetts, have joined with Pfizer Inc. in researching the use of patients' computerized records in assisting government regulators in identifying hazardous side effects of medications.

Published
2009

105. Pfizer plans to abandon heart-drug development

Author

Wang, Shirley S. and Lublin, Joann S.

Subjects
Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Pfizer Inc. -- Finance, Drugs -- Research, Drugs -- Product development, Heart diseases -- Drug therapy, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Pharmaceutical industry -- Finance, Pharmaceutical research -- Forecasts and trends, Product development -- Management, Company financing, Market trend/market analysis, Time to market, Company business management, News, opinion and commentary
Published
2008

106. Pfizer sets pacts for Alzheimer's drug

Author

Wang, Shirley S.

Subjects
Pfizer Inc. -- Product development, Pfizer Inc. -- Research, Alzheimer's disease -- Drug therapy, Clinical trials -- Reports, Drugs -- Product development, Drugs -- Research, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Research, Pharmaceutical research -- Analysis, News, opinion and commentary
Published
2008

107. Pfizer selects insider to bolster R&D; after long search, deputy to current chief steps up; 'stability and change'

Author

Johnson, Avery

Subjects
Pfizer Inc. -- Officials and employees, Pfizer Inc. -- Research, Chief executive officers -- Management, Executives -- Appointments, resignations and dismissals, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Research, Pharmaceutical research -- Management, Company business management, News, opinion and commentary
Abstract

Pfizer Inc. appoints M artin Mackay to head its research laboratories.

Published
2007

108. FDA panel backs HIV drug; Pfizer treatment blocks pathway used to infect cells

Author

Dooren, Jennifer Corbett

Subjects
United States. Food and Drug Administration -- Powers and duties, Pfizer Inc. -- Research, Pfizer Inc. -- Testing, Pfizer Inc. -- Licensing, certification and accreditation, Pfizer Inc. -- Product development, Administrative agencies -- Powers and duties, HIV infection -- Drug therapy, Pharmaceutical industry -- Research, Pharmaceutical industry -- Testing, Pharmaceutical industry -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Drug approval, News, opinion and commentary
Published
2007

109. Pfizer shake-up aims to simplify R&D; factories, 10,000 jobs are on chopping block in new products push

Author

Johnson, Avery

Subjects
Pfizer Inc. -- Research, Pfizer Inc. -- Human resource management, Pfizer Inc. -- Officials and employees, Pfizer Inc. -- Reorganization and restructuring, Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Securities, Stocks -- Prices and rates, Chief executive officers -- Management, Corporate reorganizations -- Planning, Layoffs -- Planning, Pharmaceutical industry -- Research, Pharmaceutical industry -- Human resource management, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Reorganization and restructuring, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Securities, Pharmaceutical research -- Planning, Plant shutdowns -- Planning, Profit -- Reports, Company personnel management, Company restructuring/company reorganization, Company organization, Company earnings/profit, Company securities, Company business planning, Company pricing policy, Company business management, Layoff, News, opinion and commentary
Published
2007

110. Demise of a blockbuster drug complicate's Pfizer's revamp; failure is a blow for promising heart-disease treatment; after deaths in trials

Author

Hensley, Scott and Winslow, Ron

Subjects
Pfizer Inc. -- Product defects and recalls, Pfizer Inc. -- Research, Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Product development, Anticholesteremic agents -- Product defects and recalls, Anticholesteremic agents -- Complications and side effects, Drugs -- Product defects and recalls, Drugs -- Complications and side effects, Drugs -- Product development, Drugs -- Marketing, Drugs -- Research, Pharmaceutical industry -- Product defects and recalls, Pharmaceutical industry -- Research, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Product development, Pharmaceutical research -- Evaluation, Profit -- Forecasts and trends, Cardiac patients -- Drug therapy, Cardiac patients -- Death of, Clinical trials -- Reports, Heart diseases -- Drug therapy, Company marketing practices, Company earnings/profit, Market trend/market analysis, News, opinion and commentary, Torcetrapib (Medication) -- Product defects and recalls, Torcetrapib (Medication) -- Complications and side effects
Abstract

Pfizer Inc. has had to withdraw torcetrapib, its anticholesteremic agent successor to Lipitor, after numerous deaths during clinical trials of the drug.

Published
2006

111. Pfizer tries to sell research spending

Author

Hensley, Scott

Subjects
Pfizer Inc. -- Research, Pfizer Inc. -- Product development, Pfizer Inc. -- Finance, Pfizer Inc. -- Reports, Drugs -- Research, Drugs -- Reports, Pharmaceutical industry -- Research, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Finance, Pharmaceutical industry -- Reports, Pharmaceutical research -- Reports, Company financing, News, opinion and commentary
Published
2006

112. Pfizer makes progress on diseases

Author

Hensley, Scott

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Diseases -- Research, Diseases -- United States, Banking, finance and accounting industries, Business, Business, international
Abstract

Pfizer Inc.'s scientists have made progress in research on a series of old diseases. Pfizer scientists have made progress on the SARS virus, malaria, and on smallpox.

Published
2003

113. Pfizer research

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research
Published
1984

114. New Irish institute formed to focus on trials of orphan drugs

Author

Sheridan, Cormac

Subjects
Bristol-Myers Squibb Co. -- Research, Bristol-Myers Squibb Co. -- Contracts, Pfizer Inc. -- Research, Pfizer Inc. -- Contracts, Pharmaceutical industry -- Research, Pharmaceutical industry -- Contracts, Contract agreement, Biotechnology industry, Business, Business, international
Abstract

CORK, Ireland -- Bristol-Myers Squibb Co., Pfizer Inc. and the Irish government are the initial backers of a new not-for-profit institute at University College Cork (UCC) that aims to establish [...]

Published
2003

115. Spotting defective heart valves

Author

Houlder, Vanessa

Subjects
Pfizer Inc. -- Research, Heart, Artificial -- Research, X-rays -- Research, Banking, finance and accounting industries, Business, Business, international
Published
1995

116. Pfizer to boost research funds by 11% this year

Author

Anders, George

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Banking, finance and accounting industries, Business, Business, international
Published
1994

117. Pfizer joint project shops nature's drugstore

Author

Tanouye, Elyse

Subjects
New York Botanical Garden -- Research, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Medicinal plants -- Research, Banking, finance and accounting industries, Business, Business, international
Published
1994

118. Pfizer criticises Furberg calcium antagonist study

Subjects
Pfizer Inc. -- Research, Calcium channel blockers -- Research, Business, Business, international, Pharmaceuticals and cosmetics industries
Abstract

Pfizer has criticised a study that associates increased risks of myocardial infarct (MI) with the use of short-acting calcium antagonists. Pfizer is concerned that the study will confuse patients and that the bad press may affect its long-acting calcium channel blockers for hypertension and angina, Norvasc or Procardia XL.

Published
1995

119. Pfizer and New York Botanical Garden collaborate in research and development of new medicines from U.S. plant life

Subjects
New York Botanical Garden -- Research, Pfizer Inc. -- Research, Research, Plant extracts -- Research, Medicinal plants -- Research, Materia medica, Vegetable -- Research
Abstract

Pfizer Inc., Groton, Connecticut and the New York Botanical Garden (NYBG) have entered a $2-million, three -year research collaboration to collect and study plants from within the United States as [...]

Published
1993

122. Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE)

Subjects
Pfizer Inc. -- Research, Bristol-Myers Squibb Co. -- Research, Thrombophlebitis -- Drug therapy -- Research, Anticoagulants (Medicine) -- Research -- Dosage and administration -- Health aspects, Pharmaceutical industry -- Research -- Health aspects, Health
Abstract

Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE). This study, dubbed ADVANCE-1, enrolled 3,000 subjects undergoing [...]

Published
2008

123. Renewal of research agreement

Subjects
Pharmaceutical industry -- Research, Pfizer Inc. -- Research, Oncogene Science Inc. -- Research
Abstract

Pfizer, Inc. and Oncogene Science, Inc. announced that they have renewed their five-year collaboration in cancer therapeutics for an additional five-year period. As a result of this renewal, Oncogene Science [...]

Published
1990

124. Five drug makers unveil a new arsenal of antibiotics at New Orleans conference

Author

Bishop, Jerry E.

Subjects
Merck & Company Inc. -- Research, American Cyanamid Co. -- Research, Eli Lilly and Co. -- Research, Upjohn Co. -- Research, Pfizer Inc. -- Research, Interscience Conference on Antimicrobial Agents and Chemotherapy, Pharmaceutical industry, Antibiotics -- Research, Business, Business, general
Published
1980

127. Novel public-private consortium for Alzheimer's research

Subjects
Pfizer Inc. -- Research, Alzheimer's disease -- Research, Pharmaceutical industry -- Research, Health, Psychology and mental health, Seniors, Alzheimer's Association -- Research
Abstract

The Alzheimer's Association, the Institute for the Study of Aging, and Pfizer Inc. are among the founding members of a public-private consortium designed to combat Alzheimer's disease. The consortium is [...]

Published
2003

128. Poor Phase IIb data drops Corvas' stock

Subjects
Corvas International Inc. -- Product development, Pfizer Inc. -- Research, Pharmaceutical industry -- Product development, Biotechnology industry
Abstract

Corvas International Inc. reported that preliminary analyses of a Phase llb study of UK-279,276 in ischemic stroke show that it failed to meet its primary endpoints and therefore does not [...]

Published
2002

129. Pfizer updates research on drugs

Subjects
United States. Food and Drug Administration -- Management, Pfizer Inc. -- Research, Pharmaceutical industry -- Research, News, opinion and commentary
Published
1987

130. Pfizer reports on ongoing research with 3 experimental drugs

Subjects
Pfizer Inc. -- Research, Pharmaceutical industry -- Research, Business, general, Business
Abstract

PFIZER REPORTS ON ONGOING RESEARCH WITH 3 EXPERIMENTAL DRUGS NEW YORK, Sept. 10 /PRNewswire/ -- Dr. Barry M. Bloom, president of the Central Research division of Pfizer Inc., today described [...]

Published
1987

131. Pfizer, Eisai to codevelop Alzheimer's drugs

Subjects
Pfizer Inc. -- Research, Eisai Company Ltd. -- Research, Pharmaceutical industry -- Research, Alzheimer's disease -- Drug therapy, Business, international
Published
1994

133. Pfizer, Lubrizol link with Genentech on vitamin C

Subjects
Genentech Inc. -- Research, Lubrizol Corp. -- Research, Pfizer Inc. -- Research, Vitamin C -- Research, Genetic engineering -- Research, Business, Business, international, Chemicals, plastics and rubber industries
Published
1985

Catalog

Books, media, physical & digital resources
See catalog results